Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.49 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.49 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.45 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068218 | 0.98 | CYP4F2 (0.55) | CYP4F2CYP4A11MAOAMAOBTDP1 | |
| Hydrochloric Acid SCHEMBL6985808 | 0.91 | ALOX5 (0.53) | CYP4F2CYP4A11MAOAMAOBTDP1 | |
| Hydrochloric Acid SCHEMBL6982810 | 0.90 | CYP4F2 (0.51) | CYP4F2CYP4A11MAOAMAOBPPARG | |
| SCHEMBL1068777 | 0.90 | ALOX5 (0.54) | CYP4F2CYP4A11MAOAMAOBTDP1 | |
| Hydrochloric Acid SCHEMBL28009453 | 0.89 | MAOA (0.44) | CYP4F2CYP4A11MAOAMAOBTDP1 | |
| SCHEMBL4425984 | 0.87 | CYP4F2 (0.64) | CYP4F2CYP4A11TDP1PPARGPPARA | |
| SCHEMBL8659464 | 0.87 | PPARA (0.54) | CYP4F2CYP4A11MAOAMAOBPPARG | |
| SCHEMBL19637917 | 0.87 | TDP1 (0.54) | CYP4F2CYP4A11MAOAMAOBTDP1 | |
| Hydrochloric Acid SCHEMBL6982286 | 0.85 | CYP4F2 (0.54) | CYP4F2CYP4A11TDP1PPARGPPARA | |
| Hydrochloric Acid SCHEMBL1788098 | 0.84 | SIRT2 (0.53) | CYP4F2CYP4A11MAOAMAOBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185562-B1 | PYRROLOPYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-02 | — | — | EP | disclosed |
| EP-1948624-B1 | PROCESS FOR THE PREPARATION OF BENZO[E][1,2,4]TRIAZEPIN-2-ONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-8318731-B2 | Pyrrolopyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| EP-2185562-A1 | PYRROLOPYRIMIDINES | Janssen Pharmaceutica, N.V. (BE) | 2010-05-19 | — | — | EP | disclosed |
| US-7582753-B2 | Process for the preparation of benzotriazepine derivatives | JANSSENPHARMACEUTICA, NV (BE) | 2009-09-01 | — | — | US | disclosed |
| WO-2009016132-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-05 | — | — | WO | disclosed |
| EP-1948624-A2 | PROCESS FOR THE PREPARATION OF BENZO[E][1,2,4]TRIAZEPIN-2-ONE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | disclosed |
| WO-2007035430-A2 | PROCESS FOR THE PREPARATION OF BENZO [E] [1,2,4] TRIAZEPIN-2-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | WO | disclosed |
| WO-1994022820-A1 | 1-AMIDINOPHENYL-PYRROLIDONES PIPERIDINONES AZETINONES AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-4960798-A | Methods for the treatment of angina | MCNEILAB, INC. (US) | 1990-10-02 | — | — | US | disclosed |
| US-4898889-A | Methods for the treatment of hypertension | MCNEILAB, INC. (US) | 1990-02-06 | — | — | US | disclosed |
| US-4742084-A | Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives | MCNEILAB, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| EP-0155079-B1 | ACETYLENE AMINES AND THEIR USE AS VASODILATORS AND ANTIHYPERTENSIVES | McNeilab, Inc. (US) | 1988-02-17 | — | — | EP | disclosed |
| US-4725602-A | Acetylene amines and their use as vasodilators and antihypertensives | MCNEILAB, INC. (US) | 1988-02-16 | — | — | US | disclosed |
| US-4661635-A | ANTIARRHYTHMIA AGENTS | MCNEILAB, INC. (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0155079-A1 | Acetylene amines and their use as vasodilators and antihypertensives | McNeilab, Inc. (US) | 1985-09-18 | — | — | EP | disclosed |
| EP-0146271-A2 | Aralykyl (arylethynyl) aralkyl amines for use as vasodilators and antihypertensives | McNeilab, Inc. (US) | 1985-06-26 | — | — | EP | disclosed |
| EP-0145361-A2 | Acetylene derivatives for the treatment of hypertension and angina | McNeilab, Inc. (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | MAOA 2126/4885MAOB 1718/4885PPARG 791/4885 |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | PLK4, PLK2, PLK3 | MAOA 3943/4885MAOB 3261/4885PPARG 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.